Optimizing cardiac status in the preliver transplant candidate

Curr Opin Organ Transplant. 2023 Nov 14. doi: 10.1097/MOT.0000000000001119. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Liver transplant is a widely accepted therapy for end-stage liver disease. With advances in our understanding of transplant, candidates are increasingly older with more cardiac comorbidities. Cardiovascular disease also represents a leading cause of morbidity and mortality posttransplant.RECENT FINDINGS: Preoperative cardiac risk stratification and treatment may improve short-term and long-term outcomes after liver transplant. Importantly, the appropriate frequency of surveillance has not been defined. Optimal timing of cardiac intervention in end-stage liver disease is likewise uncertain.SUMMARY: The approach to risk stratification of cardiovascular disease in end-stage liver disease is outlined, incorporating the AHA/ACC scientific statement on evaluation of cardiac disease in transplant candidates and more recent expert consensus documents. Further study is needed to clarify the ideal timing and approach for cardiovascular interventions.PMID:37991086 | DOI:10.1097/MOT.0000000000001119
Source: Current Opinion in Organ Transplantation - Category: Transplant Surgery Authors: Source Type: research